Amrubicin for relapsed Extensive-Disease small-cell lung cancer: a
systematic review and meta-analysis
Background: Amrubicin (AMR), a third-generation anthracycline and potent
topoisomerase II inhibitor, has been known to be effective treatment for
previously treated Extensive-Disease Small-Cell Lung Cancer (ED-SCLC).
However, the efficacy and toxicityof amrubicin remainsconflicting .
Thus,this meta-analysis was designed to evaluate amrubicin effectiveness
in refractory ED-SCLC patients. Methods: Pubmed, Embase, Cochrane
library databases were searched for the relevant articles. After
rigorous evaluation on quality, the data extraction process was carried
from eligible randomized controlled trials (RCTs). Meta-analysis Revman
5.3 software was used for statistical analysis. Results: A total of 7
RCTs were included in our analysis. The regimen of AMR was associate
with better progression-free survival (PFS)(OR=0.81,95%CI=0.71-0.92,
P=0.001), and the objective response rate (ORR)
(OR=1.83,95%CI=1.37-2.45, P＜0.0001＝. While, there was no statistical
significance was found in terms of the overall survival (OS)
(OR=0.90,95%CI=0.79-1.03, P=0.12). The frequencies of the most common
toxicities were more commonly occurred in the AMR group compared with
the control group were neutropenia (OR=1.67, 95%CI=1.10-2.54, P= 0.02)
and anemia (OR=0.47,95%CI=0.34-0.66, P＜0.0001＝ , respectively.
Conclusion: AMR was associated with better efficacy and acceptable side
effects for the treatment-refractory ED-SCLC. The findings revealed that
amrubicin may be used as second-line chemotherapy for patients with